Thursday, May 30, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the CogX Festival of AI and Emerging Technology in London, on June 10th.
The CogX Festival of AI and Emerging Technologybrings together more than 100 most innovative, disruptive tech startups in the world, as well as the brightest and most influential AI and emerging technology leaders to understand and experience the technology landscape trends and get the latest governmental and academic opinions on the opportunities and challenges for applications of AI and emerging technology. The CogX Festival provides an ideal platform for partnering, establishing and strengthening relationships and ecosystems with AI and emerging technology leaders from across the globe.
"We are on the brink of a technological revolution in healthcare where data collected from all different sources will influence the way we cure diseases. This approach aims to master disease treatment and extend it's branches into preventive and longevity based means. At Insilico, we are using AI as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered. We are thrilled to be able to share the results of our research at the CogX - an incredible artificial intelligence festival coming to London this June," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.
"I am really fascinated by the opportunity to participate in the CogX Festival, the event that contributes to the development of the innovative technology industries. It is such a great chance to listen to, learn from, and engage in debates with the brightest minds from the industry, and academia, and I am looking forward to sharing my own perspective as a female researcher and a deep learning scientist," said Polina Mamoshina, Senior Research Scientist at Insilico Medicine.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe ai@pharma.ai
Website: http://insilico.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Website: http://insilico.
No comments:
Post a Comment